ANDOL 100 100 mg/1 tableta tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

andol 100 100 mg/1 tableta tableta

pliva d.o.o.sarajevo - acetilsalicilna kiselina - tableta - 100 mg/1 tableta - 1 tableta sadrži: 100 mg acetilsalicilne kiseline

ANDOL GR 100 100 mg/1 tableta gastrorezistentna tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

andol gr 100 100 mg/1 tableta gastrorezistentna tableta

pliva d.o.o.sarajevo - acetilsalicilna kiselina - gastrorezistentna tableta - 100 mg/1 tableta - 1 gastrorezistentna tableta sadrži: 100 mg acetilsalicilne kiseline

PLAVIX 75 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

plavix 75 mg/1 tableta film tableta

amicus pharma d.o.o. - klopidogrel - film tableta - 75 mg/1 tableta - 1 film tableta sadrži: 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata)

ASPIRIN PROTECT 100 100 mg/1 tableta gastrorezistentna tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

aspirin protect 100 100 mg/1 tableta gastrorezistentna tableta

bayer d.o.o. sarajevo - acetilsalicilna kiselina - gastrorezistentna tableta - 100 mg/1 tableta - 1 gastrorezistentna tableta sadrži: 100 mg acetilsalicilne kiseline

ASPIRIN PROTECT 100 100 mg/1 tableta gastrorezistentna tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

aspirin protect 100 100 mg/1 tableta gastrorezistentna tableta

bayer d.o.o. sarajevo - acetilsalicilna kiselina - gastrorezistentna tableta - 100 mg/1 tableta - 1 gastrorezistentna tableta sadrži: 100 mg acetilsalicilne kiseline

Brilique Europska Unija - hrvatski - EMA (European Medicines Agency)

brilique

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antitrombotska sredstva - brilique, propisana u suradnji s ацетилсалициловой kiselina (ask), prikazana je za prevenciju атеротромботических događaja kod odraslih pacijenata withacute koronarni sindrom (acs) ora priča infarkta miokarda (im) i visokim rizikom za razvoj атеротромботических eventbrilique, uvedene zajedno sa acetil salicilna kiselina (ask), prikazana je za prevenciju атеротромботических događaja kod odraslih pacijenata s анамнезом infarkta miokarda (im dogodio ne manje od godine) i visokim rizikom od razvoja događaja атеротромботических.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Europska Unija - hrvatski - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.

Clopidogrel Krka Europska Unija - hrvatski - EMA (European Medicines Agency)

clopidogrel krka

krka, d.d., novo mesto - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - Клопидогрел prikazan odrasle za prevenciju атеротромботических događaja:pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija.

Clopidogrel Krka d.d. (previously Zopya) Europska Unija - hrvatski - EMA (European Medicines Agency)

clopidogrel krka d.d. (previously zopya)

krka, d.d., novo mesto - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - sekundarne prevencije атеротромботических eventsclopidogrel prikazuje kada:odrasli pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija. odraslih pacijenata oboljelih od akutne коронарным sindroma:bez elevacije segmenta st akutna koronarna sindrom (nestabilna angina, ili ne-q-инфарктом miokarda), uključujući i bolesnike koji su patili ugradnje stenta nakon чрескожного koronarne intervencije, u kombinaciji s ацетилсалициловой kiselinom (ask). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции fibrillationin odraslih pacijenata s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje антагонистами vitamina k (ВКА) i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europska Unija - hrvatski - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.